ArticleStatistical methods in medical research2024

A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies.

Thomas Jaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.